Louis Telesford
Cardiovascular Disease · Hamden, CTNPI 1023125523
Payments from drug & device makers
Across 1,711 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$6K
- AbbVie$6K
- AstraZeneca$5K
- Novo Nordisk$3K
- Boehringer Ingelheim$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- plus $11K from 54 others
What the payments were for
- Food & beverage$33,06598%
- Education$6742%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,739 in reported general payments places this provider in the 85th percentile of 415 cardiovascular disease providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $180,145 |
| MounjaroTirzepatide | 152 | $173,689 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $92,176 |
| FarxigaDapagliflozin Propanediol | 48 | $71,862 |
| EliquisApixaban | 49 | $69,847 |
| JardianceEmpagliflozin | 42 | $68,364 |
| EntrestoSacubitril/Valsartan | 21 | $33,140 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 22 | $31,171 |
| LinzessLinaclotide | 26 | $31,015 |
| JanuviaSitagliptin Phosphate | 16 | $27,514 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $25,378 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $20,287 |
| XareltoRivaroxaban | 20 | $19,164 |
| Colchicine | 24 | $6,190 |
| Nebivolol Hcl | 40 | $3,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,768 | $180,14593 claims |
| Lilly USA, LLCMounjaro | $505 | $173,689152 claims |
| GSKTrelegy Ellipta | $5,800 | $92,17682 claims |
| MerckJanumet Xr, Januvia, Janumet | $576 | $78,97152 claims |
| AstraZenecaFarxiga | $5,382 | $71,86248 claims |
| PfizerEliquis | $474 | $69,84749 claims |
| Boehringer IngelheimJardiance | $1,324 | $68,36442 claims |
| NovartisEntresto | $362 | $33,14021 claims |
| AbbVieLinzess | $5,769 | $31,01526 claims |
| Johnson & JohnsonXarelto | $194 | $19,16420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Hamden
- Ricardo CordidoHamden$135K
- Harlan KrumholzNew Haven$4M
- Jeffery TestaniNew Haven$3.4M
- Nihar DesaiNew Haven$3.2M
- Stuart ZarichBridgeport$1.3M
- John ForrestNew Haven$1.2M
- Hyung ChunNew Haven$1.1M
- Rohan KheraNew Haven$930K
- Brett NowlanBloomfield$798K
- Carlos Mena-HurtadoNew Haven$665K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.